232 related articles for article (PubMed ID: 16447298)
1. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
Vose JM
Hematol Oncol; 2006 Jun; 24(2):47-55. PubMed ID: 16447298
[TBL] [Abstract][Full Text] [Related]
2. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
Vose J
Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
5. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.
Martin P; Furman RR; Coleman M; Leonard JP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5636s-5642s. PubMed ID: 17875800
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
8. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
Reinis M
Curr Opin Mol Ther; 2008 Oct; 10(5):526-34. PubMed ID: 18830928
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer immunotherapy.
McNeel DG
Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
13. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma.
Winter JN
Curr Opin Hematol; 2007 Jul; 14(4):360-8. PubMed ID: 17534162
[TBL] [Abstract][Full Text] [Related]
14. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
LaCasce AS; Freedman AS
Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
[TBL] [Abstract][Full Text] [Related]
16. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma.
Borchmann P; Schnell R; Schulz H; Engert A
Curr Opin Investig Drugs; 2004 Dec; 5(12):1262-7. PubMed ID: 15648946
[TBL] [Abstract][Full Text] [Related]
18. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
19. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
20. Indolent lymphomas: current and emerging treatment approaches.
Maloney D; Kahl BS; Dreyling M
Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
